NCT01165229

Trial name or title	'Efficacy, safety and immunogenicity of GSK Biologicals' herpes zoster vaccine GSK1437173A in adults aged >= 70 years'
Methods	Allocation: randomised Endpoint classification: efficacy study Intervention model: parallel assignment Masking: double‐blind (participant, investigator, outcomes assessor) Primary purpose: prevention
Participants	14,512 healthy participants, 70 years and older, both genders
Interventions	1. Herpes zoster vaccine intramuscular injection 2. Placebo intramuscular injection
Outcomes	Confirmed HZ cases, occurrence of overall postherpetic neuralgia, safety: occurrence of adverse events (AEs)
Starting date	August 2010
Contact information	Please refer to this study by its ClinicalTrials.gov identifier: NCT01165229
Notes	This study is ongoing, but not recruiting participants. No publications provided Secondary ID: EudraCT number 2009‐015791‐94